Gadolinium contrast agent selection and optimal use for body MR imaging

Radiologic Clinics of North America

Volumn 52, Issue 4, 2014, Pages 637-656

  Guglielmo, Flavius F ^a   Mitchell, Donald G ^a   Gupta, Shiva ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Blood pool agents; Extracellular space agents; Gadolinium chelate structure and stability; Gadolinium based contrast agents; Hepatocyte specific contrast agents; Postgadolinium pulse sequences

Indexed keywords

BLOOD POOL AGENT; CONTRAST MEDIUM; EXTRACELLULAR SPACE AGENT; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM BASED CONTRAST AGENT; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; HEPATOCYTE SPECIFIC CONTRAST AGENT; UNCLASSIFIED DRUG;

ABDOMEN AND PELVIS MAGNETIC RESONANCE IMAGING; ABDOMINAL AORTA ANEURYSM; ABDOMINAL PAIN; ALLERGIC REACTION; ARTERIAL PHASE; BASELINE PRECONTRAST IMAGE; BLOOD POOL PHASE; BODY MAGNETIC RESONANCE IMAGING; CANCER STAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION RESPONSE; CONTRAST ENHANCEMENT; DIZZINESS; DRUG EXCRETION; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYNAMICS; EQUILIBRIUM CONSTANT; EXTRACELLULAR PHASE; FLIP ANGLE; FOCAL NODAL HYPERPLASIA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEPATOBILIARY PHASE; HEPATOGRAPHY; HUMAN; HYPERPLASIA; IMAGE QUALITY; INJECTION SITE COLDNESS; INJECTION SITE PAIN; INJECTION SITE WARMTH; LATE DYNAMIC PHASE; LERICHE SYNDROME; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MAGNETIC RESONANCE ENTEROGRAPHY; MEDIASTINUM; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARESTHESIA; PELVIC PAIN; PELVIS FISTULA MAGNETIC RESONANCE IMAGING; PELVIS TUMOR; PERIPHERAL VASCULAR DISEASE; PHASE TRANSITION; PHLEBOGRAPHY; PRIORITY JOURNAL; PRURITUS; RADIATION DEPTH DOSE; RADIOEMBOLIZATION; RENOGRAPHY; REVIEW; SOFT TISSUE; STEADY STATE; TIME; TREATMENT INDICATION; UNITED STATES; UROGRAPHY; VOMITING;

BLOOD POOL AGENTS; EXTRACELLULAR SPACE AGENTS; GADOLINIUM CHELATE STRUCTURE AND STABILITY; GADOLINIUM-BASED CONTRAST AGENTS; HEPATOCYTE-SPECIFIC CONTRAST AGENTS; POSTGADOLINIUM PULSE SEQUENCES;

CONTRAST MEDIA; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; WHOLE BODY IMAGING;

EID: 84901652238     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2014.02.004     Document Type: Review

References (48)

1. Gandhi S.N., Brown M.A., Wong J.G., et al. MR contrast agents for liver imaging: what, when, how. Radiographics 2006, 26(6):1621-1636.
2. Ringe K.I., Husarik D.B., Sirlin C.B., et al. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. Am J Roentgenol 2010, 195(1):13-28.
3. Prince M.R., Zhang H.L., Prowda J.C., et al. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics 2009, 29(6):1565-1574.
4. Hao D., Ai T., Goerner F., et al. MRI contrast agents: basic chemistry and safety. JMagn Reson Imaging 2012, 36(5):1060-1071.
5. Seale M.K., Catalano O.A., Saini S., et al. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 2009, 29(6):1725-1748.
6. Morcos S. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008, 66(2):175-179.
7. van der Molen A.J., Bellin M.F. Extracellular gadolinium-based contrast media: differences in diagnostic efficacy. Eur J Radiol 2008, 66(2):168-174.
8. Caravan P., Comuzzi C., Crooks W., et al. Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. Inorg Chem 2001, 40(9):2170-2176.
9. Uggeri F., Aime S., Anelli P.L., et al. Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln= Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-CS)-[4-carboxy-5, 8, 11-tris (carboxymethyl)-1-phenyl-2-oxa-5, 8, 11-triazatridecan-13-oato (5-)] gadolinate (2-) in a mixture with its enantiomer. Inorg Chem 1995, 34(3):633-643.
10. Schmitt-Willich H., Brehm M., Ewers C.L., et al. Synthesis and physicochemical characterization of a new gadolinium chelate: the liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA. Inorg Chem 1999, 38(6):1134-1144.
11. Shellock F.G., Parker J.R., Pirovano G., et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intra-and interindividual comparison studies with gadopentetate dimeglumine. JMagn Reson Imaging 2006, 24(6):1378-1385.
12. White D., DeLearie L., Moore D., et al. The thermodynamics of complexation of lanthanide (III) DTPA-bisamide complexes and their implication for stability and solution structure. Invest Radiol 1991, 26:S226-S228.
13. Reiter T., Ritter O., Prince M.R., et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. JCardiovasc Magn Reson 2012, 14(1):31.
14. Bieze M., van den Esschert J.W., Nio C.Y., et al. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. Am J Roentgenol 2012, 199(1):26-34.
15. Schuhmann-Giampieri G., Mahler M., Roll G., et al. Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans. JClin Pharmacol 1997, 37(7):587-596.
16. Tamada T., Ito K., Higaki A., et al. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol 2011, 80(3):e311-e316.
17. Van Beers B.E., Pastor C.M., Hussain H.K. Primovist, Eovist: what to expect?. JHepatol 2012, 57(2):421-429.
18. Lee N.K., Kim S., Kim G.H., et al. Significance of the "delayed hyperintense portal vein sign" in the hepatobiliary phase MRI obtained with Gd-EOB-DTPA. JMagn Reson Imaging 2012, 36(3):678-685.
19. Goodwin M.D., Dobson J.E., Sirlin C.B., et al. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 2011, 31(6):1547-1568.
20. Zech C.J., Vos B., Nordell A., et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol 2009, 44(6):305-310.
21. Motosugi U., Ichikawa T., Sou H., et al. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). JMagn Reson Imaging 2009, 30(4):849-854.
22. Davenport M.S., Viglianti B.L., Al-Hawary M.M., et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 2013, 266(2):452-461.
23. American College of Radiology. Liver Imaging Reporting and Data System version 2013.1. Available at: Accessed November 21, 2013. http://www.acr.org/Quality-Safety/Resources/LIRADS/.
24. Haradome H., Grazioli L., Tinti R., et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. JMagn Reson Imaging 2011, 34(1):69-78.
25. Lee S.A., Lee C.H., Jung W.Y., et al. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience. Magn Reson Imaging 2011, 29(1):83-90.
26. Narita M., Hatano E., Arizono S., et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. JGastroenterol 2009, 44(7):793-798.
27. Kitao A., Zen Y., Matsui O., et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging-correlation with molecular transporters and histopathologic features. Radiology 2010, 256(3):817-826.
28. Lewis M., Yanny S., Malcolm P.N. Advantages of blood pool contrast agents in MR angiography: a pictorial review. JMed Imaging Radiat Oncol 2012, 56(2):187-191.
29. Goyen M. Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag 2008, 4(1):1.
30. Hadizadeh D.R., Gieseke J., Lohmaier S.H., et al. Peripheral MR angiography with blood pool contrast agent: prospective intraindividual comparative study of high-spatial-resolution steady-state MR angiography versus standard-resolution first-pass MR angiography and DSA. Radiology 2008, 249(2):701-711.
31. Albrecht T., Willinek W.A. Peripheral vascular imaging with a blood pool contrast agent: imaging strategies and influence on patient management. Eur Radiol Suppl 2008, 18:27-34.
32. Meaney J., Goyen M. Recent advances in contrast-enhanced magnetic resonance angiography. Eur Radiol 2007, 17:B2.
33. Prince M.R., Meaney J.F. Expanding role of MR angiography in clinical practice. Eur Radiol Suppl 2006, 16:3-8.
34. Hartmann M., Wiethoff A., Hentrich H.R., et al. Initial imaging recommendations for Vasovist angiography. Eur Radiol Suppl 2006, 16:15-23.
35. Mitchell D., Cohen M. MRI principles 2004, Elsevier, Philadelphia.
36. Semelka R.C., Helmberger T.K. Contrast agents for MR imaging of the liver. Radiology 2001, 218(1):27-38.
37. Bellin M.F., Van Der Molen A.J. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 2008, 66(2):160-167.
38. Idée J.M., Port M., Raynal I., et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006, 20(6):563-576.
39. Laurent S., Elst L.V., Muller R.N. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006, 1(3):128-137.
40. Morcos S. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol 2007, 80(950):73-76.
41. Cacheris W.P., Quay S.C., Rocklage S.M. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990, 8(4):467-481.
42. Cohan R, Davenport M, Dillman J, etal. ACR Manual on Contrast Media Version 9, 2013.
43. Jeong Y.Y., Mitchell D.G., Holland G.A. Liver lesion conspicuity: T2-weighted breath-hold fast spin-echo MR imaging before and after gadolinium enhancement-initial experience. Radiology 2001, 219(2):455-460.
44. Shellock F.G., Parker J.R., Venetianer C., et al. Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance. Invest Radiol 2006, 41(6):500.
45. Kim S., Mussi T.C., Lee L.J., et al. Effect of flip angle for optimization of image quality of gadoxetate disodium-enhanced biliary imaging at 1.5 T. Am J Roentgenol 2013, 200(1):90-96.
46. Jung J.W., Kang H.R., Kim M.H., et al. Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 2012, 264(2):414-422.
47. Murphy K.J., Brunberg J.A., Cohan R. Adverse reactions to gadolinium contrast media: a review of 36cases. Am J Roentgenol 1996, 167(4):847-849.
48. Prince M.R., Zhang H., Zou Z., et al. Incidence of immediate gadolinium contrast media reactions. Am J Roentgenol 2011, 196(2):W138-W143.